DE69428441D1 - Neuartige peptidinhibitoren für opioidrezeptoren - Google Patents

Neuartige peptidinhibitoren für opioidrezeptoren

Info

Publication number
DE69428441D1
DE69428441D1 DE69428441T DE69428441T DE69428441D1 DE 69428441 D1 DE69428441 D1 DE 69428441D1 DE 69428441 T DE69428441 T DE 69428441T DE 69428441 T DE69428441 T DE 69428441T DE 69428441 D1 DE69428441 D1 DE 69428441D1
Authority
DE
Germany
Prior art keywords
opioid receptors
peptide inhibitors
new peptide
mephe4
dago
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69428441T
Other languages
English (en)
Other versions
DE69428441T2 (de
Inventor
Colette T Dooley
Richard A Houghten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrey Pines Institute for Molecular Studies
Original Assignee
Torrey Pines Institute for Molecular Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrey Pines Institute for Molecular Studies filed Critical Torrey Pines Institute for Molecular Studies
Publication of DE69428441D1 publication Critical patent/DE69428441D1/de
Application granted granted Critical
Publication of DE69428441T2 publication Critical patent/DE69428441T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C07K14/702—Enkephalins with at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69428441T 1993-05-19 1994-05-18 Neuartige peptidinhibitoren für opioidrezeptoren Expired - Fee Related DE69428441T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/064,517 US5367053A (en) 1993-05-19 1993-05-19 Opioid peptide inhibitors
PCT/US1994/005616 WO1994026296A1 (en) 1993-05-19 1994-05-18 Novel opioid peptide inhibitors

Publications (2)

Publication Number Publication Date
DE69428441D1 true DE69428441D1 (de) 2001-10-31
DE69428441T2 DE69428441T2 (de) 2002-05-23

Family

ID=22056519

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428441T Expired - Fee Related DE69428441T2 (de) 1993-05-19 1994-05-18 Neuartige peptidinhibitoren für opioidrezeptoren

Country Status (7)

Country Link
US (1) US5367053A (de)
EP (1) EP0702558B1 (de)
JP (1) JPH09508350A (de)
AT (1) ATE206137T1 (de)
CA (1) CA2163020A1 (de)
DE (1) DE69428441T2 (de)
WO (1) WO1994026296A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5919897A (en) * 1995-06-07 1999-07-06 Torrey Pines Institute For Molecular Studies MU opioid receptor ligands: agonists and antagonists
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides
US5641861A (en) * 1995-06-07 1997-06-24 Torrey Pines Institute For Molecular Studies μopioid receptor ligands: agonists and antagonists
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
US6441172B1 (en) * 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
US5965701A (en) * 1997-12-23 1999-10-12 Ferring Bv Kappa receptor opioid peptides
ATE408144T1 (de) * 2000-10-17 2008-09-15 Astrazeneca Ab Assays
US20080064046A1 (en) * 2000-10-18 2008-03-13 Astrazeneca Ab Assays
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
WO2004005318A2 (en) 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
KR100880370B1 (ko) * 2007-03-19 2009-02-03 애니젠 주식회사 유효하고 선택적인 인간 ρ2χ3 수용체 길항제로서의스피노르핀계 유도체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396606A (en) * 1979-11-05 1983-08-02 Addiction Research Foundation Novel polypeptide analgesics
CA1255586A (en) * 1984-07-24 1989-06-13 Hendrik M. Geysen Method of determining mimotopes
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IT1241761B (it) * 1990-08-03 1994-02-01 Menarini Farma Ind Peptidi di sintesi antagonisti della neurochinina a, loro sali e relativi procedimenti di fabbricazione

Also Published As

Publication number Publication date
EP0702558A1 (de) 1996-03-27
EP0702558B1 (de) 2001-09-26
WO1994026296A1 (en) 1994-11-24
JPH09508350A (ja) 1997-08-26
US5367053A (en) 1994-11-22
DE69428441T2 (de) 2002-05-23
CA2163020A1 (en) 1994-11-24
EP0702558A4 (de) 1997-02-26
ATE206137T1 (de) 2001-10-15

Similar Documents

Publication Publication Date Title
DE69428441T2 (de) Neuartige peptidinhibitoren für opioidrezeptoren
BG101841A (en) Cellular adhesion inhibitors
WO1997025351A3 (en) INHIBITORS OF MAdCAM-1-MEDIATED INTERACTIONS AND METHODS OF USE THEREFOR
DE69634492D1 (de) Medikamenten-vorstufen für thrombin-inhibitoren
DE19882126T1 (de) Hydrierung von Kohlenwasserstoffen
DE69617699D1 (de) Neuartige opioid-peptide
DE69805720D1 (de) Spendemagazin für Injektionsnadeln
WO1995025118A3 (en) Inhibitors of sh2 domain interactions
ATE384077T1 (de) Stereoselektive antifibrillogene peptide
DE69825690D1 (de) N-substituierte Perhydro-S-Triazine enthaltende Brennstoffzusammensetzungen
DE69703443T2 (de) Spender für gefalltete blätter
WO2002094767A3 (en) Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
ATE207459T1 (de) O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung
SE9503679D0 (sv) Antioxidants
DE69722618D1 (en) Peptide
DE69712523D1 (de) Flüssige kohlenwasserstoffzusammensetzungen
DE69609390D1 (de) Einspritzapparat für Kohlenwasserstoff-Einsätze
GR3027738T3 (en) Conformationally restrained peptide analogs as antiplatelet agents.
DE60104702D1 (de) Auftrennung von isomeren von n-[n-(3,3-dimethylbutyl)-l- alpha-aspartyl]-l-phenylalanin-1-methylester durch verwendung mittels metallischer ionen
DE69413432D1 (de) Piezokeramische Kapsel für Fernsprechinstrumente
MX9803791A (es) Intermediarios novedosos y su uso para preparar bisindolilmaleimidas n,n'-puenteadas.
FI965116A0 (fi) Uusia opioidipeptidiantagonisteja
Audigier et al. Binding and metabolism studies with [3H](D-Ala2, Leu5) enkephalinamide and [3H](D-Ala2, Pro5) enkephalinamide: Evidence for a selective interaction of (D-Ala2, Pro5) enkephalinamide with μ-receptors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee